SCHEMBL5652548

SCHEMBL5652548

CCc1ccc(-c2ccc(C(=O)NCC(=O)NCc3ccc(Cl)c(Cl)c3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAOK1 Q7L7X3 6/20 0.61
TAOK3 Q9H2K8 5/20 0.61
LMNA P02545 2/20 0.52
F2 P00734 1/20 0.52
F10 P00742 1/20 0.52
F7 P08709 1/20 0.52
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
MAPK1 P28482 1/20 0.51
NLRP1 Q9C000 1/20 0.51
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
EPHX2 P34913 1/20 0.49
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13026611 0.87 LMNA (0.65) LMNAHDAC4HDAC1HDAC7HDAC11
SCHEMBL14422176 0.82 TAOK1 (0.73) TAOK1TAOK3LMNAHDAC4HDAC1
SCHEMBL1926186 0.79 EPHX2 (0.67) LMNAHDAC4HDAC1HDAC7HDAC11
SCHEMBL7616443 0.76 LMNA (0.65) LMNAHDAC4HDAC1HDAC7HDAC11
SCHEMBL18130478 0.76 TRPV1 (0.59) TAOK1TAOK3LMNAF2F10
SCHEMBL31458332 0.76 TAOK1 (1.00) TAOK1TAOK3LMNAEPHX2HPGD
SCHEMBL5652402 0.76 TAOK1 (1.00) TAOK1TAOK3LMNAEPHX2HPGD
SCHEMBL8108036 0.75 EPHX2 (0.79) LMNAHDAC4HDAC1HDAC7HDAC11
SCHEMBL6361222 0.75 TSHR (0.68) TAOK1TAOK3LMNATSHRSMN1; SMN2
SCHEMBL30259914 0.75 TSHR (0.68) TAOK1TAOK3LMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208166-A1 Tao Kinase Modulators And Method Of Use EXELIXIS, INC. (US) 2007-09-06 US claimed
EP-4534091-A1 INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) 2025-04-09 EP disclosed
US-20070208166-A1 Tao Kinase Modulators And Method Of Use EXELIXIS, INC. (US) 2007-09-06 US disclosed
US-20070208166-A1 Tao Kinase Modulators And Method Of Use EXELIXIS, INC. (US) 2007-09-06 US disclosed
US-20070208166-A1 Tao Kinase Modulators And Method Of Use EXELIXIS, INC. (US) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208166-A1 Tao Kinase Modulators And Method Of Use TAOK1, TAOK3, MAP3K6 TAOK1 1/4885TAOK3 2/4885LMNA 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.